Syfrah

Syfrah is a biotechnology company dedicated to developing transformative therapies for patients with neurodegenerative and rare diseases by targeting lysosomal biology. Founded by industry veterans and backed by OrbiMed, the company focuses on restoring lysosomal function to address the underlying causes of protein misfolding and cellular dysfunction. Their approach leverages deep expertise in the lysosomal-autophagy pathway to identify novel targets and develop small molecule modulators. Syfrah's lead research efforts are directed toward conditions such as Parkinson's disease and Gaucher disease, where lysosomal impairment plays a central role in disease progression. The company aims to translate complex biological insights into a robust pipeline of precision medicines.